X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Calcipotriol,Betamethasone
Therapeutic Area: Dermatology Product Name: AKP-02
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Lipidor AB
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 07, 2020
Details:
Lipidor AB has penned an agreement with Cadila Pharmaceuticals to conduct a Phase III study for Lipidor’s drug candidate AKP-02. AKP-02 is an antipsoriasis medicine that combines the active substances calcipotriol and betamethasone with Lipidor’s spray-based AKVANO technology.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SCD-044
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited
Deal Size: $145.0 million Upfront Cash: $20.0 million
Deal Type: Licensing Agreement May 29, 2020
Details:
Sun Pharma has been granted a worldwide licence for the development and commercialization of SCD-044, which is being evaluated as a potential oral treatment for atopic dermatitis, psoriasis and other auto-immune disorders. SCD-044 is entering phase 2 clinical trials.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AUR101
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2020
Details:
The initiation of this phase II study represents a significant milestone for Aurigene, as it marks the first program which Aurigene has led from the bench side to the clinic all by itself.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
